Scholarlink

Introduction <p>Despite promising results from continuous dopaminergic stimulation (CDS)-based treatments, the effectiveness of sustained-release formulations of levodopa remains debated. This meta-analysis aims to assess the effectiveness of CDS-based levodopa treatment in patients with early to mid-stage Parkinson’s disease (PD).</p> Methods <p>Comprehensive searches were performed using PubMed, EMBASE, the Cochrane Library, Web of Science, and ClinicalTrials.gov. The clinical trials were included to compare CDS-based levodopa treatments with intermittent levodopa (IL) treatment in patients with early to mid-stage PD.</p> Results <p>A total of 18 clinical trials involving 2208 patients were included in this meta-analysis. Results showed that CDS-based levodopa treatments were associated with a significant reduction in Unified Parkinson’s Disease Rating Scale (UPDRS) II scores (mean difference (MD) − 0.79, 95%&#xa0;CI − 1.26, − 0.32) and UPDRS&#xa0;III scores (MD − 1.03, 95%&#xa0;CI − 1.98, − 0.08) compared to IL treatments. Additionally, CDS-based treatments increased ON time without troublesome dyskinesia (MD 0.63, 95%&#xa0;CI 0.35, 0.91) and decreased OFF time (MD <b>− </b>0.60, 95%&#xa0;CI <b>− </b>1.03, <b>− </b>0.18). In the subgroup analysis of UPDRS&#xa0;II scores and UPDRS&#xa0;III scores, the MD were − 0.62 (95%&#xa0;CI − 1.27, 0.02) and − 1.20 (95%&#xa0;CI − 4.74, 2.34) for 200&#xa0;mg and − 1.10 (95%&#xa0;CI − 1.88, − 0.32) and − 1.25 (95%&#xa0;CI − 3.26, 0.76) for a combination of levodopa and other drugs at varying dosages, respectively.</p> Conclusion <p>Treatment with CDS-based levodopa offers significant benefits in managing motor symptoms and reducing complications in patients with early to mid-stage PD. These therapies provide a promising alternative to traditional IL treatments, potentially leading to improving patient outcomes and quality of life.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Continuous Dopaminergic Stimulation-Based Levodopa Treatment in Patients with Early to Mid-Stage Parkinson’s Disease: A Systematic Review and Meta-Analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月28日

查看全文
  • Rong Tang,
  • Sunying Zhang,
  • Rui Sun,
  • Jiacheng Xu,
  • Yunxing Hu,
  • Hongyu Tan,
  • Ling Chen

摘要

Introduction

Despite promising results from continuous dopaminergic stimulation (CDS)-based treatments, the effectiveness of sustained-release formulations of levodopa remains debated. This meta-analysis aims to assess the effectiveness of CDS-based levodopa treatment in patients with early to mid-stage Parkinson’s disease (PD).

Methods

Comprehensive searches were performed using PubMed, EMBASE, the Cochrane Library, Web of Science, and ClinicalTrials.gov. The clinical trials were included to compare CDS-based levodopa treatments with intermittent levodopa (IL) treatment in patients with early to mid-stage PD.

Results

A total of 18 clinical trials involving 2208 patients were included in this meta-analysis. Results showed that CDS-based levodopa treatments were associated with a significant reduction in Unified Parkinson’s Disease Rating Scale (UPDRS) II scores (mean difference (MD) − 0.79, 95% CI − 1.26, − 0.32) and UPDRS III scores (MD − 1.03, 95% CI − 1.98, − 0.08) compared to IL treatments. Additionally, CDS-based treatments increased ON time without troublesome dyskinesia (MD 0.63, 95% CI 0.35, 0.91) and decreased OFF time (MD − 0.60, 95% CI − 1.03, − 0.18). In the subgroup analysis of UPDRS II scores and UPDRS III scores, the MD were − 0.62 (95% CI − 1.27, 0.02) and − 1.20 (95% CI − 4.74, 2.34) for 200 mg and − 1.10 (95% CI − 1.88, − 0.32) and − 1.25 (95% CI − 3.26, 0.76) for a combination of levodopa and other drugs at varying dosages, respectively.

Conclusion

Treatment with CDS-based levodopa offers significant benefits in managing motor symptoms and reducing complications in patients with early to mid-stage PD. These therapies provide a promising alternative to traditional IL treatments, potentially leading to improving patient outcomes and quality of life.